▲ Peaking
Business
What would it take to get peptides on the shelf?
NPR examines the regulatory and commercial hurdles involved in bringing peptide-based products to retail shelves.
Pharmaceuticals
38 trends tracked about this subject — the full history, oldest to newest below.
↑ Rising
Business
AstraZeneca investors baulk at $400 billion Bristol Myers talks
AstraZeneca investors are resisting proposed acquisition talks with Bristol Myers valued at $400 billion.
▲ Peaking
Business
AstraZeneca Shares Fall on Deal Talks With Bristol-Myers
AstraZeneca shares decline as reports emerge regarding potential multi-billion-dollar merger talks with Bristol-Myers Squibb.
▲ Peaking
Science
Deadly blooms offer a genetic blueprint for making hard-to-synthesize medicinal compounds
Researchers are leveraging the genetic blueprints of deadly flowers to develop hard-to-synthesize medicinal compounds.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk rocked by late-stage cardiovascular drug failure
Pharmaceutical giant Novo Nordisk faces a significant setback following the failure of a late-stage cardiovascular drug trial.
◼ Archived
Health
🔮 fades ✓
New, more efficient pill to lower cholesterol
FDA approves first oral PCSK9 inhibitor for adults with high cholesterol, changing treatment options.
◼ Archived
Business
🔮 fades ✗
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK is launching a $2.5 billion cost-saving initiative to accelerate its late-stage drug pipeline and relocate its research headquarters.
◼ Archived
Business
🔮 holds ✓
Johnson & Johnson offers to pay $5.5bn to settle baby powder lawsuits
Johnson & Johnson has proposed a $5.5 billion settlement to resolve a decade-long legal battle over cancer claims linked to its baby powder.
◼ Archived
Business
🔮 fades ✓
Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
Logistics giants are aggressively expanding cold storage infrastructure to accommodate a surge in GLP-1 drug demand and a broader healthcare boom.
◼ Archived
Business
🔮 fades
US FDA approves over-the-counter Tylenol combination pill for pain relief
The US FDA has approved the first over-the-counter combination of acetaminophen and naproxen sodium for extended pain relief.
◼ Archived
Business
🔮 fades
With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access
Merck is establishing global access and licensing frameworks for the world's first monthly oral HIV prevention pill ahead of its official approval.
◼ Archived
Business
🔮 fades
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi is scrapping plans for an eczema drug derived from its billion-dollar Kymab acquisition following a strategic pipeline review.
◼ Archived
Business
🔮 fades
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
◼ Archived
Business
🔮 fades
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Donald Trump is proposing 100% tariffs on generic drugs starting in 2028 as part of a strategic Made-in-USA initiative.
◼ Archived
Business
🔮 fades
Trump’s 100% Generic Drug Duty Threatens US Low-Cost Supply
Donald Trump has announced plans for 100% tariffs on imported generic drugs starting in 2028 to push for U.S. pharmaceutical onshoring.
◼ Archived
Business
🔮 fades
Trump Sets 100% Tariff on Generic Drugs With Two-Year Delay
President Trump has announced a phased tariff plan on generic drugs starting in 2028 to incentivize domestic U.S. pharmaceutical production.
◼ Archived
Business
🔮 holds
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
◼ Archived
Business
🔮 fades
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has launched a legal offensive against Eli Lilly, alleging that the competitor's GLP-1 weight-loss drug advertising is deceptive.
◼ Archived
Business
🔮 fades
Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia
Bristol Myers Squibb is partnering with Nvidia to construct what it claims will be the most powerful AI supercomputer in the pharmaceutical industry.
◼ Archived
Business
🔮 fades
Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide
Samsung Biologics is pursuing a $1.8 billion all-cash acquisition of Swiss CDMO PolyPeptide to expand its global peptide manufacturing network.
◼ Archived
Business
🔮 holds
The F.D.A. Approves a New Pill to Slash Cholesterol Levels
The FDA has approved a first-of-its-kind daily oral pill from Merck designed to slash cholesterol levels.
◼ Archived
Business
🔮 fades
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
An experimental Alzheimer's drug shows early promise while raising mixed questions and triggering a stock drop.
◼ Archived
Business
🔮 fades
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio (QTTB) shares surged following positive phase 2 clinical trial results for its alopecia areata drug, Bempikibart.
◼ Archived
Business
🔮 fades
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the publication of Complete Response Letters (CRLs), releasing 14 drug rejection letters following a three-month disclosure freeze.
◼ Archived
Business
🔮 fades
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Medicare is now offering $50 GLP-1 prescriptions. The US may never be the same.
Medicare has introduced $50 prescriptions for GLP-1 medications, signaling a potential shift in the US healthcare and pharmaceutical landscape.
◼ Archived
Business
🔮 fades
Alibaba, U.S. Payment Processor to Pay $600 Million in DOJ Settlement Over Illegal Drug Sales
Alibaba and a U.S. payment processor have agreed to a $600 million settlement with the Department of Justice regarding illegal product sales.
◼ Archived
Business
🔮 fades
What older adults need to know before taking a GLP-1 medication to lose weight
Recent reporting examines why Medicare policy fails to transform the market prospects for weight-loss drug manufacturers.
◼ Archived
Health
🔮 fades
As weight loss drugs like Ozempic spread, Louisiana doctors, researchers help answer big questions
GLP-1 weight‑loss drugs spark a wave of research, clinical guidance and market buzz as they expand beyond obesity treatment.
◼ Archived
World
🔮 fades
Explosions, fires reported in Kyiv amid Russian missile attack
Explosions and fires hit Kyiv as a Russian missile strike severely damages the Darnytsia pharmaceutical plant.
◼ Archived
Business
🔮 fades
Sanofi under antitrust probe as European Commission kicks off formal proceedings
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades
New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks
Research into GLP-1 receptor agonists is shifting focus from weight management to potential longevity benefits and broader therapeutic applications.
◼ Archived
Health
🔮 fades
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Oral GLP-1 medications are gaining attention as clinical data emerges regarding their efficacy in weight management and potential to shift treatment paradigms.
◼ Archived
Business
🔮 fades
Loophole in Patent Law Brings ‘Miracle Drug’ to Patients Who Can’t Afford It
Beximco Pharma has initiated the supply of a low-cost cystic fibrosis medication to patients across six countries following a patent law loophole.
◼ Archived
Business
🔮 fades
AbbVie’s biggest deal since 2019 could land soon
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Cure for certain cancers is ‘realistic’ goal in next decade, pharma lead says
Johnson & Johnson CEO Joaquin Duato identifies the development of cures for certain types of cancer as a realistic objective for the coming decade.
◼ Archived
Business
🔮 holds
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 holds
Doctors Inject Human Subjects With First Vaccine Designed by AI
Clinical trials are underway for the world’s first universal coronavirus vaccine created entirely through artificial intelligence.